Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - November 2012

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Aclidinium (Eklira®) has been accepted for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Adalimumab (Humira®) has been rejected for use in the treatment of moderately active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. The manufacturer failed to make a submission.

Nepafenac (Nevanac®) has been accepted for use to reduce the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Ranolazine (Ranexa®) has been rejected for use as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. The manufacturer failed to make a sufficiently robust clinical and economic case.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - November 2012' on Email Share 'SMC Update - November 2012' on Delicious Share 'SMC Update - November 2012' on Digg Share 'SMC Update - November 2012' on Facebook Share 'SMC Update - November 2012' on reddit Share 'SMC Update - November 2012' on Twitter

atomic-wealth

No Comments to “SMC Update - November 2012”

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer